Zendal is the corporate brand of the biotechnology group that brings together eight brands focused on the research, development, manufacture and marketing of human and animal health vaccines and other biological, pharmaceutical and nutritional products with high added value for the health sector. The companies under its umbrella are CZ Vaccines, Biofabri, Probisearch, Vetia, Petia, Zinereo, Laboratorios Ovejero and Laboratorios Maymó.
The business model is based on continuous innovation in the field of biotechnology and pharmaceuticals. Zendal is committed to preventive medicine and its future plan includes the development of several vaccines for the prevention of some of today’s most relevant diseases. To this end, Zendal is constantly investing in technology and production facilities and has a large team of scientists with solid training and experience fully dedicated to research.
Today, the company has a team of more than 650 people, most of them highly qualified. During 2020, the workforce increased by 20% due to the acceleration of its growth plan driven by its involvement in covid19 vaccine manufacturing projects.
It has multiple differentiated areas of biotechnological and pharmaceutical production in different locations in Spain and northern Portugal, which positions it as a preferential location for the production of vaccines in Spain. It is the first company in Spain with authorization to manufacture vaccines for human use and one of the few in Europe.
It currently exports its animal and human health products to 65 countries.